StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a report released on Monday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Trading Up 2.8 %
TTNP opened at $3.69 on Monday. Titan Pharmaceuticals has a 1-year low of $3.03 and a 1-year high of $14.80. The company has a 50 day simple moving average of $3.59 and a two-hundred day simple moving average of $4.13.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last posted its quarterly earnings results on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) EPS for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
See Also
- Five stocks we like better than Titan Pharmaceuticals
- How to Invest in the FAANG Stocks
- How to Build the Ultimate Everything ETF Portfolio
- Most Volatile Stocks, What Investors Need to Know
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- What is an Earnings Surprise?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
